CO2020009271A2 - Compuestos que pueden usarse como inhibidor tumoral, método de preparación de los mismos y aplicación de los mismos - Google Patents

Compuestos que pueden usarse como inhibidor tumoral, método de preparación de los mismos y aplicación de los mismos

Info

Publication number
CO2020009271A2
CO2020009271A2 CONC2020/0009271A CO2020009271A CO2020009271A2 CO 2020009271 A2 CO2020009271 A2 CO 2020009271A2 CO 2020009271 A CO2020009271 A CO 2020009271A CO 2020009271 A2 CO2020009271 A2 CO 2020009271A2
Authority
CO
Colombia
Prior art keywords
compound
preparation
application
tumor inhibitor
compounds
Prior art date
Application number
CONC2020/0009271A
Other languages
English (en)
Inventor
Lei Yin
Zhenglin Yao
Heng Li
Original Assignee
Gan&Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan&Lee Pharmaceuticals filed Critical Gan&Lee Pharmaceuticals
Publication of CO2020009271A2 publication Critical patent/CO2020009271A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto que puede usarse como un inhibidor tumoral, un método para su preparación y la aplicación del mismo. El compuesto tiene una estructura representada por la fórmula general I; se incluyen un estereoisómero, un enantiómero, un racemato, un isómero cis/trans, un tautómero y una variante isotópica del compuesto; el compuesto puede usarse por separado o en combinación con otros fármacos para tratar tumores o enfermedades inflamatorias, o para tratar otros trastornos o enfermedades mediadas por la actividad de MDM2 y/o MDM4, y muestra una actividad curativa prominente.
CONC2020/0009271A 2017-12-29 2020-07-28 Compuestos que pueden usarse como inhibidor tumoral, método de preparación de los mismos y aplicación de los mismos CO2020009271A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711484280 2017-12-29
PCT/CN2018/122796 WO2019128877A1 (zh) 2017-12-29 2018-12-21 一种可用作肿瘤抑制剂的化合物及其制备方法与应用

Publications (1)

Publication Number Publication Date
CO2020009271A2 true CO2020009271A2 (es) 2020-08-10

Family

ID=67066531

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0009271A CO2020009271A2 (es) 2017-12-29 2020-07-28 Compuestos que pueden usarse como inhibidor tumoral, método de preparación de los mismos y aplicación de los mismos

Country Status (16)

Country Link
US (1) US11339171B2 (es)
EP (1) EP3733676A4 (es)
JP (1) JP2021508727A (es)
KR (1) KR20200105837A (es)
CN (1) CN112041320B (es)
AU (1) AU2018398881A1 (es)
BR (1) BR112020013069A2 (es)
CA (1) CA3087110A1 (es)
CL (1) CL2020001685A1 (es)
CO (1) CO2020009271A2 (es)
EA (1) EA202091583A1 (es)
IL (1) IL275667A (es)
MX (1) MX2020006816A (es)
PE (1) PE20211908A1 (es)
SG (1) SG11202006262TA (es)
WO (1) WO2019128877A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ611866A (en) * 2010-11-12 2015-04-24 Univ Michigan Spiro-oxindole mdm2 antagonists
JP5992054B2 (ja) * 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
JO3357B1 (ar) * 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
JP6171003B2 (ja) * 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
JP6577958B2 (ja) * 2014-04-11 2019-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用
WO2015161032A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same
CA2947134A1 (en) * 2014-06-12 2015-12-17 Adamed Sp. Z O.O. Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
WO2016001376A1 (en) * 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
MX2018004207A (es) * 2015-10-09 2018-07-06 Boehringer Ingelheim Int Nuevos compuestos de espiro[3h-indol-3,2â´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.

Also Published As

Publication number Publication date
CN112041320B (zh) 2023-05-23
SG11202006262TA (en) 2020-07-29
MX2020006816A (es) 2020-09-03
BR112020013069A2 (pt) 2020-12-01
KR20200105837A (ko) 2020-09-09
EP3733676A4 (en) 2021-09-01
JP2021508727A (ja) 2021-03-11
WO2019128877A1 (zh) 2019-07-04
CL2020001685A1 (es) 2020-09-25
US20210079007A1 (en) 2021-03-18
EP3733676A1 (en) 2020-11-04
EA202091583A1 (ru) 2020-10-08
AU2018398881A1 (en) 2020-08-06
US11339171B2 (en) 2022-05-24
PE20211908A1 (es) 2021-09-28
CA3087110A1 (en) 2019-07-04
IL275667A (en) 2020-08-31
CN112041320A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
CL2018001667A1 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
NI201600071A (es) Compuestos de inhibidor de autotaxina
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
CL2016003092A1 (es) “compuestos derivados de pirazol sustituido, bloqueadores de canales de calcio tipo t; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, enfermedades del snc, cardiovasculares, neuropatía diabética, infertilidad y disfunción sexual”. pct
ECSP14030779A (es) Inhibidores del nampt
CO2018001621A2 (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
GT201500247A (es) Imidazopiridazinas sustituidas
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia